Glaxo had been hoping to receive second-round bids for a clutch of its non-prescription drugs—which include its diet pill Alli, Lactacyd soap, FiberChoice diet supplements and Nytol sleep aid—by mid-November, Reuters reported in October.
The brands, which are mainly available in the United States and Europe, account for about 10 percent of Glaxo’s revenue from consumer products in 2010. A spokesperson for Thomas H. Lee declined to comment. GlaxoSmithKline was not immediately available for comment.
Private equity firms
(Soham Chatterjee is a correspondent for Reuters in Bangalore.)